Edition:
India

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

2.74USD
22 Aug 2019
Change (% chg)

$0.03 (+1.11%)
Prev Close
$2.71
Open
$2.69
Day's High
$2.79
Day's Low
$2.66
Volume
1,178,407
Avg. Vol
2,177,320
52-wk High
$18.44
52-wk Low
$2.34

Select another date:

Tue, Aug 13 2019

Why would allegedly defrauded Akorn investors want … more Akorn stock?

The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to acquire Akorn, is suing Akorn in Delaware Chancery Court for damages from the busted deal. The U.S. Food and Drug Administration is investigating data integrity issues at the company’s manufacturing plants, issuing two warning letters this year about potential regulatory shortcomings. Akorn is also feeling p

Akorn gets FDA warning letter for another manufacturing plant

Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

Akorn gets FDA warning letter for another manufacturing plant

Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant

June 25 Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

Akorn gets FDA's warning letter related to New Jersey manufacturing plant

June 25 Akorn Inc said on Tuesday the U.S. Food and Drug Administration has raised certain issues related to the inspection of its Somerset, New Jersey manufacturing facility in July and August of 2018.

FDA flags concerns at Akorn's Amityville plant, shares slip

Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

UPDATE 2-FDA flags concerns at Akorn's Amityville plant, shares slip

Feb 28 Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

FDA flags sanitation concerns at Akorn's Amityville plant

Feb 28 Akorn Inc said on Thursday the U.S. Food and Drug Administration issued observations related to inspection of the company's manufacturing facility in Amityville, New York.

Select another date: